The results were promising because 1) the primary fibroblasts were much less sensitive to tozasertib and nutlin-3 than p53 wild-type and p53-mutant neuroblastoma cells and 2) the combination of tozasertib and nutlin-3 resulted in contrast to the effects observed in p53 wild-type neuroblastoma cells not in enhanced toxicity compared to either single treatment (Figure S2). Here, TP53 is linked to neuroblastoma.